As­traZeneca cuts PhI­II ALS study af­ter Alex­ion's Ul­tomiris shows 'lack of ef­fi­ca­cy'

Alex­ion has con­ced­ed its first de­feat since of­fi­cial­ly be­com­ing a sub­sidiary of As­traZeneca.

Fol­low­ing an in­ter­im analy­sis, the rare dis­ease-fo­cused group says it will scrap a Phase III study test­ing the long-act­ing C5 in­hibitor Ul­tomiris as a treat­ment for amy­otroph­ic lat­er­al scle­ro­sis. Since start­ing in Jan­u­ary 2020, the tri­al has en­rolled 382 pa­tients, per tri­al records. All of them will now stop tak­ing study med­ica­tion — ei­ther Ul­tomiris or place­bo — and com­plete any nec­es­sary fol­low-up eval­u­a­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER